The FDA evaluated the New Drug Application (NDA) for Joenja® under priority review and has approved the drug based on findings from a multinational, triple-blind, placebo-controlled, randomized ...

The newly licensed drug, leniolisib, is the first targeted treatment for her condition, Activated PI3-kinase Delta Syndrome or APDS. Not only is Mary the first patient to benefit from the drug but her ...